环境、病原体与宿主在类鼻疽病中的相互作用 (DeEPH)
解码三元关系:类鼻疽中环境、病原体与宿主之间的相互作用(DeEPH)
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.
The hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.
For each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
This study is funded by the Wellcome Trust. The grant reference number is 323077/Z/24/Z
研究概览
地位
条件
详细说明
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems:
- Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand (MORU);
- Mahosot Hospital, Vientiane, Lao PDR (LOMWRU); and
- Angkor Hospital for Children, Siem Reap, Cambodia (COMRU).
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
Participant Recruitment and Follow-up
Hospital cohort:
Patients with melioidosis will be recruited at all three hospital sites. The study plans to recruit 1,000 patients, who will be followed longitudinally at six time points: Day 0 (admission), Days 3 and 7 (acute phase), and Days 30, 180, and 365 (recovery phase).
Clinical data collected will include demographic characteristics, underlying comorbidities, environmental exposures, lifestyle and behavioural factors, treatment history, patient-reported medication adherence, and follow-up outcomes.
Healthy controls:
Each patient will be matched with a healthy control recruited within two weeks of diagnosis, based on age, sex, and village of residence. Controls will have no current symptoms or prior history of melioidosis. They will provide a single blood sample at enrolment for DNA extraction and antibody profiling and will be followed up by telephone on Days 180 and 365.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Kamolchanok Claire Chewapreecha, PhD
- 电话号码:662 203 6333
- 邮箱:claire@tropmedres.ac
学习地点
-
-
-
Siem Reap、柬埔寨
- 尚未招聘
- Cambodia-Oxford Medical Research Unit (COMRU)
-
接触:
- Paul Turner, MD
- 邮箱:Pault@tropmedres.ac
-
-
-
-
-
Ubon Ratchathani、泰国
- 招聘中
- Sunpasitthiprosong Hospital
-
接触:
- Kamolchanok C Chewapreecha, PhD
- 电话号码:022036333
- 邮箱:claire@tropmedres.ac
-
-
-
-
-
Vientiane、老挝
- 尚未招聘
- Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)
-
接触:
- Elizabeth Ashley, MD
- 邮箱:Elizabeth.Ashley@tropmedres.ac
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Melioidosis patients:
Patients confirmed to have melioidosis.
Healthy controls:
For each confirmed melioidosis case, a healthy control-defined as having no current fever, no evidence of soft tissue infection, and no prior history of melioidosis-will be recruited from satellite blood bank donors within approximately two weeks of case identification. Controls will be matched by age (±5 years), sex, and village of residence.
Sandbox Village residents:
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation.
描述
Inclusion criteria for melioidosis patients:
- Age ≥20 years
- Positive for Burkholderia pseudomallei from any clinical samples
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for healthy controls:
- Age ≥20 years
- Currently healthy as judged by study doctor
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for sandbox residents:
- Age ≥20 years
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Exclusion criteria for melioidosis patients:
- Current tuberculosis (TB) or TB treatment within the past six months
- Documented HIV infection or use of immunosuppressive therapy in the past 12 months
Exclusion criteria for healthy controls:
- History of melioidosis
- Significant acute illness
- Current fever or soft tissue infection
Exclusion criteria for sandbox residents
-N/A
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Melioidosis patients
Patients confirmed to have melioidosis |
|
Healthy controls
Healthy controls will be enrolled for each confirmed melioidosis case. A healthy control is defined as an individual with no current fever, no evidence of soft tissue infection, and no prior history of melioidosis. Controls will be recruited within approximately two weeks of case identification and will be matched to cases by age (±5 years), sex, and village of residence. |
|
Sandbox village cohort
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation. |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
在类鼻疽病例中评估暴露后类鼻疽病的发展情况
大体时间:365天
|
365天
|
|
健康对照组中暴露后类鼻疽病的发展情况评估
大体时间:365 天
|
365 天
|
|
沙盒村居民接触后类鼻疽病发生情况评估
大体时间:3.5年
|
3.5年
|
|
类鼻疽患者(类鼻疽病例)在感染急性期的死亡率。
大体时间:365天
|
365天
|
|
因类鼻疽病(类鼻疽病例)出院后再次入院的患者数量。
大体时间:365天
|
365天
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
环境改变相互作用导致的暴露后疾病发展变化。
大体时间:3.5年
|
3.5年
|
|
暴露后急性感染期死亡率变化与环境改造相互作用有关。
大体时间:365天
|
365天
|
|
环境改造相互作用相关康复后医院再入院率变化
大体时间:365天
|
365天
|
|
临床管理因素相互作用后,暴露相关的疾病发展变化。
大体时间:365天
|
365天
|
|
在急性感染期,与临床管理因素相互作用相关的暴露后死亡率变化。
大体时间:365天
|
365天
|
|
临床管理因素相互作用相关的康复后医院再入院率变化。
大体时间:365 天
|
365 天
|
|
暴露后与遗传易感性相互作用相关的疾病发展变化。
大体时间:365天
|
365天
|
|
感染急性期死亡率的变化,与涉及遗传易感性的相互作用相关。
大体时间:365天
|
365天
|
|
与遗传易感性相关的相互作用导致的康复后再次入院变化。
大体时间:365天
|
365天
|
合作者和调查者
调查人员
- 首席研究员:Kamolchanok Claire Chewapreecha, PhD、Mahidol Oxford Tropical Research Unit
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The study outputs, including genomic and transcriptomic data and associated metadata, will be valuable for future research. In compliance with the Wellcome Trust's open data policies and to encourage reproducibility, data will be deposited in two repositories:
Human genomic and transcriptomic data: European Genome-Phenome Archive (EGA), under managed access
Bacterial genomic data: European Nucleotide Archive (ENA), open access
Pseudonymised metadata, including participant demographics and microbiological findings, will be shared with qualified researchers in accordance with the General Data Protection Regulation (GDPR). No personally identifiable information will be shared, and participants will not be identifiable from any released data.
IPD 共享支持信息类型
- 研究方案
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.